Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Merck Sharp & Dohme LLC820 enrolled

Overview

The purpose of this study is to determine the efficacy and tolerability of an investigational drug for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

820

Conditions

Nausea Vomiting Breast Neoplasms

Interventions

MK0869, aprepitant / Duration of Treatment: 3 daysDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with a diagnosis of breast cancer requiring treatment with non-cisplatin moderately emetogenic chemotherapy. * Patient must have completed participation in the main study for this protocol. Exclusion Criteria: * Patient has a central nervous system malignancy. * Patient will receive radiation to the abdomen or pelvis.

Outcomes

Primary Outcomes

Safety and tolerability

Secondary Outcomes

Assessment of adverse experiences using the National Cancer Institute (NCI) criteria

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.